AR029739A1 - Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas - Google Patents
Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomasInfo
- Publication number
- AR029739A1 AR029739A1 ARP990104680A ARP990104680A AR029739A1 AR 029739 A1 AR029739 A1 AR 029739A1 AR P990104680 A ARP990104680 A AR P990104680A AR P990104680 A ARP990104680 A AR P990104680A AR 029739 A1 AR029739 A1 AR 029739A1
- Authority
- AR
- Argentina
- Prior art keywords
- microadenomas
- parkinson
- disease
- treatment
- adhd
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- PJEAHOHAPYWSEB-UHFFFAOYSA-N 4h-pyrido[1,2-a]pyrazine Chemical class C1=CC=CN2CC=NC=C21 PJEAHOHAPYWSEB-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere al uso de ciertos derivados de pirido [1,2-a]-pirazina, también descritos como compuestos bis-azabicíclicos y definidos por la formula 1de este documento, en el tratamiento de la enfermedad de Parkinson, el trastorno de hiperactividad con déficit de atencion y microadenomas en mamíferos, y a composiciones relacionadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10119198P | 1998-09-21 | 1998-09-21 | |
| US10386898P | 1998-10-12 | 1998-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029739A1 true AR029739A1 (es) | 2003-07-16 |
Family
ID=26798000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104680A AR029739A1 (es) | 1998-09-21 | 1999-09-17 | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US6300329B1 (es) |
| EP (1) | EP1115402A1 (es) |
| JP (1) | JP2002526448A (es) |
| KR (3) | KR20040054752A (es) |
| CN (1) | CN1319013A (es) |
| AP (1) | AP1456A (es) |
| AR (1) | AR029739A1 (es) |
| AU (1) | AU760230B2 (es) |
| BG (1) | BG105445A (es) |
| BR (1) | BR9913975A (es) |
| CA (1) | CA2344670A1 (es) |
| CO (1) | CO5140075A1 (es) |
| CZ (1) | CZ20011006A3 (es) |
| DZ (1) | DZ2894A1 (es) |
| EA (2) | EA200100204A1 (es) |
| EE (1) | EE200100179A (es) |
| GE (1) | GEP20033081B (es) |
| GT (1) | GT199900154A (es) |
| HN (1) | HN1999000146A (es) |
| HR (1) | HRP20010209A2 (es) |
| HU (1) | HUP0103691A3 (es) |
| ID (1) | ID28028A (es) |
| IL (2) | IL141507A0 (es) |
| IS (1) | IS5852A (es) |
| MA (1) | MA26690A1 (es) |
| MY (1) | MY127939A (es) |
| NO (1) | NO20011409L (es) |
| NZ (1) | NZ509855A (es) |
| OA (1) | OA11653A (es) |
| PA (1) | PA8482001A1 (es) |
| PE (1) | PE20001084A1 (es) |
| PL (1) | PL346904A1 (es) |
| SK (1) | SK3592001A3 (es) |
| TN (1) | TNSN99177A1 (es) |
| TR (2) | TR200101357T2 (es) |
| TW (1) | TW518225B (es) |
| WO (1) | WO2000016777A1 (es) |
| YU (1) | YU21701A (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1999000146A (es) * | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
| US8030294B2 (en) * | 2000-03-16 | 2011-10-04 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AU2002315336A1 (en) * | 2001-06-18 | 2003-01-02 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5ht-1a agonists |
| US20030036555A1 (en) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma Kg | Pramipexole for the treatment of ADHD |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| EP1765075A4 (en) * | 2004-06-10 | 2010-11-10 | Mclean Hospital Corp | PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS |
| WO2006020703A1 (en) * | 2004-08-11 | 2006-02-23 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
| MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
| GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| PE20070523A1 (es) | 2005-09-12 | 2007-06-28 | Wyeth Corp | Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| WO2008083442A1 (en) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Method for formulating combination medications for adhd |
| CN101318020B (zh) * | 2007-06-06 | 2011-09-28 | 四川科瑞德制药有限公司 | 抗焦虑或/和抗抑郁的药物组合物及用途 |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| GB201112987D0 (en) | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
| CN104892589A (zh) | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| WO2016186968A1 (en) | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX19222A (es) * | 1989-01-23 | 1993-12-01 | Pfizer | Agentes ansioliticos bis-aza-biciclicos |
| WO1992000075A1 (en) * | 1990-06-29 | 1992-01-09 | Pfizer Inc. | Pyridopyrazine derivatives for treating substance abuse and addiction |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| GB9408084D0 (en) * | 1994-04-23 | 1994-06-15 | Boots Co Plc | Medical treatment |
| MX9606450A (es) * | 1994-06-14 | 1997-03-29 | Pfizer | Derivados de bencimidazolona. |
| US5877183A (en) * | 1996-06-06 | 1999-03-02 | Ergo Research Corporation | Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists |
| HN1999000146A (es) * | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
-
1999
- 1999-08-27 HN HN1999000146A patent/HN1999000146A/es unknown
- 1999-09-03 TR TR2001/01357T patent/TR200101357T2/xx unknown
- 1999-09-03 EA EA200100204A patent/EA200100204A1/ru unknown
- 1999-09-03 KR KR10-2004-7006381A patent/KR20040054752A/ko not_active Ceased
- 1999-09-03 CA CA002344670A patent/CA2344670A1/en not_active Abandoned
- 1999-09-03 JP JP2000573738A patent/JP2002526448A/ja active Pending
- 1999-09-03 AU AU53831/99A patent/AU760230B2/en not_active Ceased
- 1999-09-03 NZ NZ509855A patent/NZ509855A/xx unknown
- 1999-09-03 GE GEAP19995812A patent/GEP20033081B/en unknown
- 1999-09-03 TR TR2004/02083T patent/TR200402083T2/xx unknown
- 1999-09-03 EP EP99939567A patent/EP1115402A1/en not_active Withdrawn
- 1999-09-03 OA OA1200100068A patent/OA11653A/en unknown
- 1999-09-03 HR HR20010209A patent/HRP20010209A2/hr not_active Application Discontinuation
- 1999-09-03 IL IL14150799A patent/IL141507A0/xx unknown
- 1999-09-03 YU YU21701A patent/YU21701A/sh unknown
- 1999-09-03 HU HU0103691A patent/HUP0103691A3/hu unknown
- 1999-09-03 EE EEP200100179A patent/EE200100179A/xx unknown
- 1999-09-03 KR KR10-2003-7014169A patent/KR20030088512A/ko not_active Ceased
- 1999-09-03 WO PCT/IB1999/001503 patent/WO2000016777A1/en not_active Ceased
- 1999-09-03 KR KR10-2001-7003552A patent/KR100468340B1/ko not_active Expired - Fee Related
- 1999-09-03 CZ CZ20011006A patent/CZ20011006A3/cs unknown
- 1999-09-03 IL IL16483999A patent/IL164839A0/xx unknown
- 1999-09-03 EA EA200301063A patent/EA200301063A1/ru unknown
- 1999-09-03 ID IDW20010637A patent/ID28028A/id unknown
- 1999-09-03 AP APAP/P/2001/002102A patent/AP1456A/en active
- 1999-09-03 SK SK359-2001A patent/SK3592001A3/sk unknown
- 1999-09-03 CN CN99811132A patent/CN1319013A/zh active Pending
- 1999-09-03 BR BR9913975-8A patent/BR9913975A/pt not_active IP Right Cessation
- 1999-09-03 PL PL99346904A patent/PL346904A1/xx unknown
- 1999-09-13 GT GT199900154A patent/GT199900154A/es unknown
- 1999-09-15 PA PA19998482001A patent/PA8482001A1/es unknown
- 1999-09-15 TW TW088115941A patent/TW518225B/zh not_active IP Right Cessation
- 1999-09-17 AR ARP990104680A patent/AR029739A1/es unknown
- 1999-09-17 PE PE1999000948A patent/PE20001084A1/es not_active Application Discontinuation
- 1999-09-17 MY MYPI99004051A patent/MY127939A/en unknown
- 1999-09-20 MA MA25774A patent/MA26690A1/fr unknown
- 1999-09-20 DZ DZ990194A patent/DZ2894A1/xx active
- 1999-09-20 TN TNTNSN99177A patent/TNSN99177A1/fr unknown
- 1999-09-21 US US09/400,659 patent/US6300329B1/en not_active Expired - Fee Related
- 1999-09-21 CO CO99059863A patent/CO5140075A1/es unknown
-
2001
- 2001-02-20 IS IS5852A patent/IS5852A/is unknown
- 2001-03-20 NO NO20011409A patent/NO20011409L/no not_active Application Discontinuation
- 2001-04-13 BG BG105445A patent/BG105445A/xx unknown
- 2001-05-03 US US09/848,068 patent/US6608064B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029739A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| MY135902A (en) | SUBSTITUTED HEXAHYDROPYRAZINO [1, 2-a] PYRIMIDINE-4, 7-DIONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
| BRPI0413022A (pt) | derivados de 3-amino cromado e 2-amino tetralina | |
| TW200510417A (en) | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments | |
| ECSP088297A (es) | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-e]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA | |
| ECSP066391A (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| CR6726A (es) | Compuestos azapoliciclicos condensados con arilo | |
| ATE469892T1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
| ECSP066669A (es) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos | |
| ECSP034924A (es) | Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno | |
| AR063188A1 (es) | Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol | |
| UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
| ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
| BRPI0412809A (pt) | compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 | |
| UY28377A1 (es) | Agentes terapeuticos | |
| SE9702563D0 (sv) | Compounds | |
| DE502006004182D1 (de) | Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2-aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln | |
| MXPA04001419A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson. | |
| DE69911785D1 (de) | Triazolo[4,5-d]pyrimidin-verbindungen | |
| CR8162A (es) | Piridinylanilides | |
| CR6308A (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| ECSP993150A (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| ATE429435T1 (de) | 7h-pyrrolopyrimidinderivate | |
| ATE345343T1 (de) | Triazolo(4,5-d)pyrimidinderivate als antithrombotische verbindungen | |
| ES2100257T3 (es) | Acidos 2-arilpropenoicos y su uso para la preparacion de s-cetoprofeno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |